Evidence map›Paper›PMID 34015620›Full record

ArticleVirology2021

Frequency of HLA alleles among COVID-19 infected patients: Preliminary data from Saudi Arabia.

Fatmah M A Naemi, Shurooq Al-Adwani, Heba Al-Khatabi, Ashwaq Al-Nazawi

Open access · greenAbstract read
In one paragraph

Article in Virology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed, 2 pooled it
1.3field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 2 syntheses or guidelines pooled it, 24 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Review
  10. Article
  11. PeerJ · 2023
    Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. MHC Variants Associated With SymptomaticFrontiers in immunology · 2021
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Fatmah M A NaemiHistocompatibility and Immunogenetics Laboratory, King Fahd General Hospital, Ministry of Health, Jeddah, Saudi Arabia. Electronic address: fnaemi@moh.gov.sa.
Shurooq Al-AdwaniHistocompatibility and Immunogenetics Laboratory, King Fahd General Hospital, Ministry of Health, Jeddah, Saudi Arabia. Electronic address: shaladwani@moh.gov.sa.
Heba Al-KhatabiCenter of Excellence in Genomic Medicine Research, King Fahd Medical Research Center, King Abdul-Aziz University, Jeddah, Saudi Arabia. Electronic address: halkhattabi@kau.edu.sa.
Ashwaq Al-NazawiPublic Health VBD, Ministry of Health, Jeddah, Saudi Arabia. Electronic address: amalnazawi@moh.gov.sa.
Ministry of Health · SAKing Abdul Aziz University Hospital · SA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

HLA polymorphism is one of the genetic factors that may be associated with variations in susceptibility to COVID-19 infection. In this study, the frequency of HLA alleles among Saudi patients infected with COVID-19 was examined. The association with infection susceptibility and mortality was evaluated. This study included 135 Saudi COVID-19-infected patients (106 recovered and 29 died) who were admitted to hospitals because of their symptoms, and 135 healthy controls. HLA class I (A, B, C) and class II (DRB1, DQB1) genotyping was performed using the molecular method (PCR-rSSO). In this study, there was a significant increase in the frequency of HLA-A*01, B*56 and C*01 among infected patients compared to the control group (12.1% vs. 5.2%, p = 0.004, 3.7% vs. 0%, p = 0.006, 4.4% vs. 1.5%, p = 0.042, respectively). Moreover, there was a significant increase in the frequency of HLA-A*03 and C*06 among fatal patients compared to infected patients (13.8% vs. 5.7%, p = 0.036, 32.8% vs. 17.5%, p = 0.011, respectively). In terms of HLA class II, HLA-DRB1*04 was significantly higher in the control group compared to infected patients (27.4% vs. 16.3%, p = 0.002), while HLA-DRB1*08 was significantly higher in the infected group compared to the control (4.8% vs. 0.7%, p = 0.004). After statistical correction of the p value, A*01, B*56, DRB1*04 and DRB1*08 remained statistically significant (p

Indexed as

Age DistributionAllelesCOVID-19FemaleGene FrequencyGenetic Predisposition to DiseaseGenotypeHLA AntigensHumansMalePolymorphism, GeneticPreliminary DataRiskSARS-CoV-2Saudi ArabiaSex DistributionHLA AntigensCOVID-19HLA polymorphismMortalitySaudiSusceptibility

Identifiers

PMID34015620
PMCPMC8100873
OpenAlexW3157409939

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.